Table 3.
Effect of different treatment regimens* on FVC† of patients with COPD during study period
| Treatment groups* | Mean (SD) FVC† | Mean difference (95% CI) | P value | |
|---|---|---|---|---|
| First recording | Last recording | |||
| ICS (n=204) | 2.75 (0.94) | 2.78 (0.97) | 0.03 (−0.03 to 0.09) | 0.369 |
| ICS+BB (n=43) | 2.58 (0.82) | 2.71 (0.87) | 0.13 (−0.02 to 0.28) | 0.086 |
| ICS+LABA (n=459) | 2.61 (0.94) | 2.71 (0.97) | 0.10 (0.05 to 0.14) | <0.001 |
| ICS+LABA+BB (n=89) | 2.63 (0.89) | 2.69 (0.87) | 0.06 (−0.05 to 0.15) | 0.287 |
| ICS+LABA+Tio (n=753) | 2.46 (0.89) | 2.48 (0.84) | 0.02 (−0.01 to 0.06) | 0.241 |
| ICS+LABA+Tio+BB (n=88) | 2.40 (0.88) | 2.50 (0.89) | 0.10 (−0.01 to 0.20) | 0.08 |
| LABA or Tio (no ICS) (n=197) | 2.67 (0.93) | 2.66 (0.93) | 0.01 (−0.07 to 0.05) | 0.767 |
| BB (no ICS) (n=276) | 2.91 (0.84) | 2.80 (0.89) | 0.11 (0.05 to 0.16) | <0.001 |
| ICS+Tio (n=81) | 2.48 (0.81) | 2.59 (0.75) | 0.11 (0.01 to 0.20) | 0.043 |
| (LABA or Tio)+BB (n=47) | 2.77 (0.93) | 2.82 (0.95) | 0.05 (−0.05 to 0.17) | 0.297 |
| Control‡ (n=475) | 2.90 (0.96) | 2.86 (0.95) | −0.04 (−0.09 to −0.02) | 0.041 |
*Treatments: ICS=inhaled corticosteroid, BB=β blocker, LABA=long acting β agonist, Tio=tiotropium.
†FVC=forced vital capacity (litres).
‡Control=treatment only with short acting β agonists with or without short acting antimuscarinic agent.